Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Pulmonary Embolism

In brief

Phase II trial of TS23

Key facts

Study ID

NCT05408546

Run by

Translational Sciences, Inc.

People needed

64

Starts

2023-05-24

Expected to finish

2026-11-01

Last updated by the study team

2026-07-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female subjects, age >18 years;
• PE involving a segmental or more proximal pulmonary artery confirmed by CTPA scan and with an onset of symptoms not more than 5 days prior to diagnosis;
• Subject is hemodynamically stable with a systolic blood pressure (SBP) >90 mm Hg;
• Subject has evidence of RV dysfunction as indicated by a right ventricular-to-left ventricular (RV/LV) diameter ratio > 0.9 on CTPA scan (measuring the minor axis of the right and left ventricle in the transverse plane), prior to the initiation of study drug administration.

You may not qualify if…

• Subjects for whom thrombolytic therapy or thrombectomy is planned; or subjects with history of administration of thrombolytic agents within the previous 4 days;
• Subjects receiving ≥ 48 hours of therapeutic doses of heparin or low molecular weight heparin (LMWH) or other anticoagulant therapy immediately prior to randomization;
• Subjects with contraindications to SOC therapies such as unfractionated heparin or LMWH or oral anticoagulant, or any of the excipients (including study drug excipients);
• Subjects who are considered at very high risk of bleeding:
• Known coagulation disorder with history of pathologic bleeding tendencies
• Subjects with prior intracranial hemorrhage, known arteriovenous malformation or aneurysm of the brain, or evidence of active bleeding;
• Subjects with a history of major surgery, clinically significant head trauma (in the opinion of the Principal Investigator), or stroke in the past 3 months prior to randomization;
• Subjects with uncontrolled hypertension defined as SBP ≥180 mm Hg and/or diastolic BP (DBP)
• ≥110 mm Hg at randomization
• Subjects requiring concomitant dual antiplatelet therapy
• Subjects with Creatinine Clearance (CrCL) < 30 mL/min or serum creatinine ≥ 2.5 mg/dL;
• Subjects with hemoglobin < 8.0 g/dL;
• Subjects with a platelet count < 100,000/µL;
• Subjects with acute or persistent hepatitis or diagnosed active liver disease or with elevation of liver enzymes: Alanine transaminase (ALT) or aspartate transaminase (AST) ≥ 3 x upper limit of normal (ULN);
• Subjects with known history of testing positive for Hepatitis B antigen or Hepatitis C antibody;
• Subjects with known history of testing positive for the human immunodeficiency virus (HIV);
• Subjects with life-expectancy < 6 months;
• Female subjects of child bearing potential with a positive pregnancy test or who are lactating, or unwilling to use highly effective methods of contraception. Highly effective methods of birth control include combination hormonal therapy (estrogen and progresterone), contraceptives administered orally, intravaginally or transdermally, progesterone-only contraceptives administered orally, by injection or implantation, use of an intrauterine device (IUD), intrauterine hormone- releasing system (IUS), bilateral tubal occlusion, partner vasectomy or sexual abstinence;
• Subjects currently participating in another investigational study or who have participated in an investigational drug study within 30 days (or longer depending on the half-life of the investigational drug; should allow at least five half-life of the investigational drug) prior to randomization.

Where it is running

• Banner University Medical Center — Phoenix, Arizona, United States
• Banner University Medical Center - Tucson — Tucson, Arizona, United States
• Cedars Sinai Medical Center — Los Angeles, California, United States
• Cottage Hospital — Santa Barbara, California, United States
• Wellstar MCG Health Medical Center — Augusta, Georgia, United States
• Lifebridge Health — Baltimore, Maryland, United States
• Tuft University Hospital — Boston, Massachusetts, United States
• Henry Ford Hospital — Detroit, Michigan, United States
• Wake Forest University/Atrium Health's Carolinas Medical Center — Winston-Salem, North Carolina, United States
• Fairview Hospital — Cleveland, Ohio, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• Temple University Hospital — Philadelphia, Pennsylvania, United States
• Texas Tech University Health Sciences Center at El Paso — El Paso, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.